Inside Eli Lilly’s Strategic Investment In Sigilon: An Opportunity Overlooked
jetcityimage Pharma giant Eli Lilly and Company (NYSE:LLY) is buying the tiny biotech Sigilon Therapeutics, Inc. (NASDAQ:SGTX) for $14.92 per share in cash. The shares are trading at $21.28 due to a contingent value right ((CVR)) from Eli Lilly, potentially worth as much as $111.64 per share. Eli Lilly and Sigilon worked together on cell…